1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+)
This is an abbreviated version!
For detailed information about 15-hydroxyprostaglandin dehydrogenase (NAD+), go to the full flat file.
Word Map on EC 1.1.1.141
-
1.1.1.141
-
cox-2
-
cyclooxygenase-2
-
fetal
-
arachidonic
-
pregnancy
-
chorion
-
labor
-
pgf2alpha
-
indomethacin
-
parturition
-
nsaid
-
trophoblast
-
preterm
-
myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
-
decidua
-
synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
-
osteoarthropathy
-
prostacyclin
-
amnion
-
beta-hydroxysteroid
-
lipoxins
-
calcitriol
-
9-ketoreductase
-
medicine
-
slco2a1
-
6-keto-pgf1
-
drug development
- 1.1.1.141
- cox-2
- cyclooxygenase-2
- fetal
-
arachidonic
- pregnancy
- chorion
- labor
-
pgf2alpha
- indomethacin
-
parturition
-
nsaid
- trophoblast
-
preterm
- myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
- decidua
- synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
- osteoarthropathy
- prostacyclin
- amnion
-
beta-hydroxysteroid
-
lipoxins
- calcitriol
-
9-ketoreductase
- medicine
-
slco2a1
-
6-keto-pgf1
- drug development
Reaction
Synonyms
11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase, 15-hydroxy prostaglandin dehydrogenase, 15-hydroxy-prostaglandin-dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 15-hydroxyprostanoic dehydrogenase, 15-OH-PGDH, 15-PGDH, 15-prostaglandin dehydrogenase, dehydrogenase, 15-hydroxyprostaglandin, HPGD, NAD+ dependent 15-hydroxyprostaglandin dehydrogenase, NAD+ dependent PGDH, NAD+-15-hydroxy prostanoate oxidoreductase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I), NAD+-dependent 15-PGDH, NAD+-linked 15-hydroxyprostaglandin dehydrogenase, NAD-dependent 15-hydroxyprostaglandin dehydrogenase, NAD-specific 15-hydroxyprostaglandin dehydrogenase, nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase, PGDH, prostaglandin dehydrogenase
ECTree
1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)Advanced search results
results (
results (Activating Compound
Activating Compound on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
ACTIVATING COMPOUND 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
erlotinib
-
epidermal growth factor receptor tyrosine kinase inhibitor, trreatment of cells increases the expression of the enzyme in a subset of non-small-cell lung cancer lines
pioglitazone
-
upregulation of expression, involving peroxisome proliferator-activated receptor gamma. Upregulation results in reduced production of prostaglandin E2 and finally inhibition of lung cancer growth
rosiglitazone
-
upregulation of expression, involving peroxisome proliferator-activated receptor gamma. Upregulation results in reduced production of prostaglandin E2 and finally inhibition of lung cancer growth
Thionicotinamide adenine dinucleotide
-
5-33% of the activity with NAD+, depending on substrate
additional information
-
12-O-tetradecanoylphorbol-13-acetate induces the synthesis of 15-PGDH but inhibits the enzyme activity a protein kinase C mediated mechanism
-
additional information
-
enzyme activation leads to reduced cell proliferation
-
additional information
-
enzyme expression is inducible by indomethacin in LS174T cells, but not in HCA-7 and HCT-15 cells, and also not in enzyme-deficient HCT-116
-
additional information
-
enzyme up-regulation by the tumor suppressor gene CAAT/enhancer binding protein alpha
-
additional information
-
the enzyme is induced by the androgens dihydrotestosterone or testosterone and, to a lesser extent, by 17beta-estradiol and progesterone in androgen-sensitive LNCaP cells, not in hormone-independent PC3 cells, the induction of 15-PGDH is not blocked by steroid receptor antagonist RU 486 nor by antiandrogen, flutamide, but is inhibited by tyrosine kinase inhibitor, genistein, and by ERK kinase inhibitor, PD 98059, but not by protein kinase C inhibitor GF109203X, thus androgens induce 15-PGDH gene expression through an unconventional nongenomic pathway, no induction by dexamethasone, hydrocortisone, and RU 486
-
additional information
-
15-PGDH expression is increased by hepatocyte nuclear factor 3beta in lung cancer cells
-
additional information
-
flurbiprofen induces 15-PGDH expression in cancer cells, PD98059 and U-0126 elevate 15-PGDH levels very significantly
-
additional information
-
treatment of colorectal cancer cells with 5-aza-2'-deoxycytidine, 5 mM sodium butyrate or 5 mM valproic acid induces an increase in 15-PGDH protein expression
-
additional information
-
a 42- to 55-fold induction of the PGDH activity is observed after 20 days of gestation in pregnant rabbits
-
